Seres Therapeutics (MCRB) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update
November 10, 2016 7:30 AM EST
- Analyses of SER-109 Phase 2 results on track for completion by year
end;
Company intends to discuss proposed future SER-109
clinical development plans with the FDA -
- Pipeline progress with SER-287 and SER-262 Phase 1b study execution;
data
read-outs continue to be expected in 2017 -
- New microbiome patent strengthens the Companys intellectual property estate -
- Conference call at 8:00 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More
